Abstract: An electrode formed by molding a semiconductor device with resin. The electrode comprises: a first resin mold portion formed on a front surface of the semiconductor device and having a first thickness (t1); a second resin mold portion formed on a back surface of the semiconductor device and having a second thickness (t2) greater than the first thickness; and an exposed portion formed in a part of the first resin mold portion corresponding to an end of the semiconductor device.

Abstract: We achieved the present invention on the basis of the finding that an excellent therapeutic effect against pancreatic cancer can be obtained by administering an IL-6 inhibitor and an antimetabolite to pancreatic cancer patients. We also found that metastatic lesions from human pancreatic cancer can be reduced and ascites can be eliminated.

Abstract: We achieved the present invention on the basis of the finding that an excellent therapeutic effect against pancreatic cancer can be obtained by administering an IL-6 inhibitor and an antimetabolite to pancreatic cancer patients. We also found that metastatic lesions from human pancreatic cancer can be reduced and ascites can be eliminated.

Abstract: We achieved the present invention on the basis of the finding that an excellent therapeutic effect against pancreatic cancer can be obtained by administering an IL-6 inhibitor and an antimetabolite to pancreatic cancer patients. We also found that metastatic lesions from human pancreatic cancer can be reduced and ascites can be eliminated.

Abstract: The purpose of the present invention is to provide an anticancer agent for potentiating an antitumor effect, alleviating side effects, and further extending the survival rate by concomitant use with a component having an anticancer effect. An anticancer agent combining arctigenin and a component other than arctigenin that has an anticancer effect, in which the anticancer agent may be a combination drug or may be a kit configured from a formulation containing arctigenin and a formulation containing a component that has an anticancer effect, and the concomitant use of arctigenin and the component having an anticancer effect more strongly inhibits tumor growth and reduces the proportion of cancer stem cells in the tumor, making it possible to extend the total survival time and to alleviate side effects caused by the component having an anticancer effect.

Abstract: The present invention is intended to provide a novel anticancer agent which is effective to a cancer. After administering an agent prepared using burdock fruit extract to a pancreas cancer patient so that a dose of arctigenin was 100 mg or more per day, the tumor reducing effect was observed, and, in addition, lowering of tumor markers was confirmed. The present invention provides an anticancer agent containing arctigenin, wherein a dose of the arctigenin is 100 mg or more per day. In addition, the present invention provides the anticancer agent containing arctigenin and arctiin at a weight ratio of arctigenin/arctiin=0.7 to 1.3.

Abstract: The present invention relates to a marker allowing specific detection of human IL-17-producing helper T-cells (human Th17 cells), a method for specifically detecting human Th17 cells and a reagent for detecting human Th17 cells.

Abstract: We achieved the present invention on the basis of the finding that an excellent therapeutic effect against pancreatic cancer can be obtained by administering an IL-6 inhibitor and an antimetabolite to pancreatic cancer patients. We also found that metastatic lesions from human pancreatic cancer can be reduced and ascites can be eliminated.

Abstract: The present invention is intended to provide a novel anticancer agent which is effective to a cancer. After administering an agent prepared using burdock fruit extract to a pancreas cancer patient so that a dose of arctigenin was 100 mg or more per day, the tumor reducing effect was observed, and, in addition, lowering of tumor markers was confirmed. The present invention provides an anticancer agent containing arctigenin, wherein a dose of the arctigenin is 100 mg or more per day. In addition, the present invention provides the anticancer agent containing arctigenin and arctiin at a weight ratio of arctigenin/arctiin=0.7 to 1.3.

Abstract: The present invention relates to polynucleotide markers and protein markers for detecting human follicular helper T cells. The present invention also relates to methods for detecting human follicular helper T cells using the markers.

Abstract: An object is to provide a method for evaluating presence of rheumatoid arthritis by using a new biomarker set. The object is achieved by a method for evaluating presence of rheumatoid arthritis, in which the method includes the steps of: acquiring, from a biological specimen obtained from a subject, information regarding expression level of a first biomarker which is SLC16A4, and information regarding expression level of at least one second biomarker selected from the group consisting of SLCO2B1, PTPRM, SHB, and ATP9A; and evaluating presence of rheumatoid arthritis in the subject based on the information regarding expression levels of the acquired first and second biomarkers.

Abstract: The present invention relates to a marker allowing specific detection of human IL-17-producing helper T-cells (human Th17 cells), a method for specifically detecting human Th17 cells and a reagent for detecting human Th17 cells.

Abstract: We achieved the present invention on the basis of the finding that an excellent therapeutic effect against pancreatic cancer can be obtained by administering an XL-6 inhibitor and an antimetabolite to pancreatic cancer patients. We also found that metastatic lesions from human pancreatic cancer can be reduced and ascites can be eliminated.

Abstract: The present invention relates to a marker allowing specific detection of human IL-17-producing helper T-cells (human Th17 cells), a method for specifically detecting human Th17 cells and a reagent for detecting human Th17 cells.

Abstract: Disclosed is at least one polynucleotide marker or protein marker which enables the specific detection of an IL-17-producing helper T cell (a Th17 cells). Also disclosed is a method for detecting a Th17 cell, which is characterized by comprising detecting the occurrence of the above-mentioned at least one marker.

Abstract: Disclosed is a polynucleotide marker or a protein marker for use in the specific detection of an IL-17-producing helper T-cell (a Th17 cell). Also disclosed is a method for detecting a Th17 cell, which is characterized by detecting the occurrence of the polynucleotide marker or the protein marker.

Abstract: The invention provides a process for obtaining low-nitrogen steel by tapping molten steel from a converter without deoxidizing and by then deoxidizing the molten steel in a ladle refining furnace from which slag has been removed, and a process for obtaining low phosphorus steel by tapping molten steel from a converter without deoxidation at a tapping temperature lower than conventional processes, and by performing deoxidation and composition adjustment of the molten steel in a ladle refining furnace from which slag has been removed.

Abstract: Molten steel is tapped from a converter into a refining ladle, and an ore such as Nb.sub.2 O.sub.3 ore is charged into the molten steel. Then, the interior of the refining ladle is held in an inert gas atmosphere. A reducing agent such as an Al reducing agent is charged into the molten steel. Electrodes are dipped in slag on the molten steel to form an arc therebetween so as to heat the molten steel with an arc. The ore is reduced by the reducing agent, so that a metallic component of the ore is added to the molten steel. On the other hand, carbon electrodes each having a gas supply port at its lower end can be used to inject an ore powder or particles from the injection ports to the arc between the electrodes and molten steel. The ore is reduced by electrode carbon with arc heat, so that a desired component is added to the molten steel.

Abstract: The invention relates to a method of operating a ladle refining furnace for blowing Ar gas through bubbling lances submerged in molten steel in a ladle to stir the molten steel. The flow rate and the rate of change in the flow rate of the Ar gas blown through the bubbling lances are adjusted to prevent the iron lumps from attaching to the bubbling lances.

Abstract: Nondeoxidized molten steel is removed from a steel converter and poured into a ladle. Carbon electrodes are submerged in a slag layer on the molten steel and are separated by a predetermined distance from the molten steel. The electrodes are energized to generate arcs with the molten steel. Argon gas is blown into the molten steel through a lance submerged in the molten steel to stir the molten steel with the gas. The molten steel is arc-heated and at the same time stirred. Carbon in the molten steel reacts with residual unstable oxygen in the steel to deoxidize the molten steel. The molten steel is also decarburized, thereby preventing an increase in carbon content of the molten steel in the arc process.